Luca Bianchi

Beyond Psoriasis Skin Clearance: Effects of Bimekizumab and Tildrakizumab on Systemic Inflammation and Immune-Nutrition Status

Background/Objectives: Psoriasis is a chronic immune-mediated inflammatory disease associated with a high systemic burden. Inhibition of the IL-23/IL-17 axis is the cornerstone of therapy, although the evaluation of immune-nutritional status in the assessment of psoriatic disease...

Cemiplimab in cutaneous squamous cell carcinoma: a longer follow‐up study focusing on the late toxicities

Summary Background and Objectives Cemiplimab was the first systemic therapy approved for advanced cutaneous squamous cell carcinoma (cSCC). Patients and Methods We report findings from the Italian early access program cohort, comprising 134 patients treated with cemiplimab, with...